Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARVN Arvinas Holding Company LLC

Trading 12-11 15:53:53 EST

12.59

-0.39

-3.04%

High13.15	Low12.47	Vol869.33K
Open12.99	D1 Closing12.98	Amplitude5.28%
Mkt Cap808.26M	Tradable Cap808.26M	Total Shares64.22M
T/O11.04M	T/O Rate1.35%	Tradable Shares64.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":12.585,"timestamp":1765486432726,"preClose":12.98,"halted":0,"volume":869329,"delay":0,"floatShares":64224294,"shares":64224294,"eps":-0.80523,"marketStatus":"Trading","change":-0.395,"latestTime":"12-11 15:53:53 EST","open":12.99,"high":13.15,"low":12.4653,"amount":11035716.985067,"amplitude":0.05275,"askPrice":12.59,"askSize":501,"bidPrice":12.58,"bidSize":406,"shortable":3,"etf":0,"ttmEps":-0.80523,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":12.98,"preHourTrading":{"tag":"盘前","latestPrice":13.05,"preClose":12.98,"latestTime":"09:18 EST","volume":102340,"amount":1329213.61608,"timestamp":1765462699026},"postHourTrading":{"tag":"盘后","latestPrice":12.99,"preClose":12.98,"latestTime":"19:53 EST","volume":153637,"amount":1996070.61,"timestamp":1765414410730},"volumeRatio":0.758777,"impliedVol":0.5865,"impliedVolPercentile":0.124},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"2589825151","title":"Arvinas Announces Phase 1 Trial of ARV-393 and Glofitamab Combination for Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825151","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825151?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:05","pubTimestamp":1765026310,"startTime":"0","endTime":"0","summary":"Arvinas Inc. announced new preclinical data supporting the combination of ARV-393, a PROTAC BCL6 degrader, with glofitamab, a CD20×CD3 bispecific antibody, as a potential chemotherapy-free treatment strategy for diffuse large B-cell lymphoma . The results were presented at the 2025 American Society of Hematology  Annual Meeting and Exposition. In a humanized high-grade B-cell lymphoma cell line-derived xenograft model, the combination demonstrated significantly enhanced tumor growth inhibition and increased tumor regression compared to either agent alone. Arvinas plans to initiate a Phase 1 clinical trial cohort evaluating the ARV-393 and glofitamab combination in patients with DLBCL in 2026 and expects to share clinical data from the ongoing Phase 1 trial of ARV-393 in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL7425zt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4007","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","ARVN","BK4585","BK4112","BK4588","SG9999014005.SGD"],"gpt_icon":0},{"id":"2585829461","title":"Arvinas Highlights Vepdegestrant Breast Cancer Data at 2025 SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2585829461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585829461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985616,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has announced that multiple abstracts related to vepdegestrant , an investigational PROTAC estrogen receptor degrader, have been accepted for presentation at the upcoming 2025 San Antonio Breast Cancer Symposium , scheduled for December 9-12, 2025. The presentations will include subgroup analyses from the phase 3 VERITAC-2 trial comparing vepdegestrant to fulvestrant in ER-positive/HER2-negative advanced breast cancer, circulating tumor DNA biomarker analyses from a phase 1/2 study, and early clinical data on the combination of vepdegestrant with the KAT6 inhibitor PF-07248144. The results will be presented at the symposium and full abstracts are available via the SABCS online program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8kF9JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","ARVN","BK4007","LU2210150020.SGD","BK4112","BK4585","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584925074","title":"Arvinas Q3 Revenue USD 41.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925074","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925074?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570317,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Arvinas Q3 operating expenses USD 85.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:54.667 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbnGZhG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2584951336","title":"Arvinas Up Over 21%, On Track for Largest Percent Increase Since December 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2584951336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584951336?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:59","pubTimestamp":1763481540,"startTime":"0","endTime":"0","summary":"Arvinas, Inc.  is currently at $13.38, up $2.34 or 21.23%. --Would be highest close since March 10, 2025, when it closed at $17.56. --On pace for largest percent increase since Dec. 6, 2023, when it rose 30.77%. --Currently up three consecutive days; up 32.25% over this period. --Down 87.59% from its all-time closing high of $107.87 on July 29, 2021. --Down 38.15% from 52 weeks ago , when it closed at $21.64. --Down 49.91% from its 52-week closing high of $26.72 on Nov. 29, 2024. --Traded as high as $13.60; highest intraday level since March 10, 2025, when it hit $18.45. --Up 23.19% at today's intraday high; largest intraday percent increase since Dec. 6, 2023, when it rose as much as 33.75%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"1182005516","title":"Stock Track | Arvinas Soars 5.08% as Stephens Raises Price Target and Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1182005516","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182005516?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:05","pubTimestamp":1762787153,"startTime":"0","endTime":"0","summary":"Shares of Arvinas Holding Company LLC (ARVN) are soaring 5.08% in Monday's intraday trading session, following positive analyst actions from Stephens & Co. The biotechnology company's stock is...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ARVN"],"gpt_icon":0},{"id":"2582872072","title":"Arvinas Is Maintained at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872072?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:23","pubTimestamp":1762784580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:23 ET (14:23 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581094600","title":"Arvinas Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094600?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:37","pubTimestamp":1762439820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 09:37 ET (14:37 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581195721","title":"Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581195721","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581195721?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:06","pubTimestamp":1762344367,"startTime":"0","endTime":"0","summary":"Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40.96 percent. This is a 29.41 percent increase over losses of $(0.68) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649256/arvinas-q3-eps-0-48-beats-0-81-estimate-sales-41-900m-beat-23-600m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581072152","title":"Arvinas Reports Positive Phase 1 Data and Advances Pipeline in Q3 2025 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072152","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072152?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:03","pubTimestamp":1762344215,"startTime":"0","endTime":"0","summary":"Arvinas Inc. announced its third quarter 2025 financial results and provided a corporate update. The company reported positive data from Phase 1 clinical trials of ARV-102 in both healthy volunteers and patients with Parkinson's disease. Preclinical data from ARV-806 showed robust and differentiated activity in models of KRAS G12D-mutated cancer. Additionally, preclinical data from ARV-027 demonstrated significant degradation of polyQ-AR in muscle, supporting further evaluation as a potential disease-modifying therapy in spinal bulbar muscular atrophy . Arvinas also announced an agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant. The company highlighted these developments as part of its ongoing efforts to advance its PROTAC degrader portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL5Khkdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1066053197.SGD","LU0225771236.USD","BK4550","LU0225284248.USD","BK4592","SG9999013999.USD","BK4599","BK4534","LU0456855351.SGD","SG9999001176.SGD","LU1066051498.USD","LU0868494617.USD","IE00B19Z3B42.SGD","BK4007","IE00BLSP4239.USD","BK4588","BK4533","LU0122379950.USD","SG9999001176.USD","SG9999003800.SGD","LU0306806265.USD","SG9999002224.SGD","BK4568","SG9999002232.USD","ARVN","LU0170899867.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU0234572021.USD","LU0321505439.SGD","SG9999011175.SGD","IE00BBT3K403.USD","BK4585","LU0289739699.SGD","LU0058720904.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1057294990.SGD","SGXZ57979304.SGD","LU0321505868.SGD","BK4581","LU1023059063.AUD","LU1894683264.USD","IE00B19Z3581.USD","LU1894683348.USD","LU1883839398.USD"],"gpt_icon":1},{"id":"2581472160","title":"BRIEF-Arvinas Q3 Revenue USD 41.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581472160","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581472160?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344054,"startTime":"0","endTime":"0","summary":"BRIEF-Arvinas Q3 Revenue USD 41.9 Million\n\n\nNov 05 (Reuters) - Arvinas Q3 operating expenses USD 85.7 million.\n\nQ3 pretax profit USD -34.8 million\nQ3 operating income USD -43.8 million\nQ3 net income USD -35.1 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX98332D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581729472","title":"Arvinas Q3 Operating Expenses USD 85.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581729472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581729472?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344009,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX98332D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2581724404","title":"Arvinas Inc:  Q3 EPS $-0.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724404?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX98332D:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581025729","title":"Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581025729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581025729?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA8PY8SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2581767579","title":"Top News Today: Stocks Slide as Artificial Intelligence Optimism Cools","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767579?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:41","pubTimestamp":1762292460,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields declined as the government shutdown dragged on.COMMODITIES: Oil futures retreated as traders digested the OPEC+ decision to raise output in December and pause increases in the first quarter of next year.Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup. Drugmakers Novo Nordisk and Pfizer raised their offers in the multibillion-dollar takeover battle for obesity-drug developer Metsera, the latest twist in their unusual fight over the startup.Metsera said Tuesday that Novo Nordisk's proposal values the biotech company at up to $86.20 a share, or approximately $10 billion, up from its previous bid of $9 billion. This valuation represents an approximately 159% premium to Metsera's closing price on Sept. 19, the last trading day before the Pfizer deal was disclosed.Rivian recorded a loss of $1.17 billion, or 96 cents a share, compared with a loss of $1.1 billion, or $1.08 a share, a year earlier. Analysts expected a loss of 88 cents, according","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"240d82993489181f2c14fbceebaca07a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4189","LU2023250330.USD","FIS","IE0034390439.USD","IE00BVYPNW00.USD","PMI","TECH","ANIK","PFE","LU1732799900.SGD","BK4122","LU1778281490.HKD","LU0795875169.SGD","CHH","LU0077335932.USD","LU2360106780.USD","FVRR","LU1066051225.USD","CNK","AES","GPRE","LU0320765489.SGD","TSYW.SI","BK4527","ARCB","BG","LU0082616367.USD","LU0266013472.USD","DOCN","ARVN","LU0053666078.USD","MTSR","FTDR","LU0251131958.USD","AVNS","SG9999015986.USD","IE00BLSP4452.SGD","LU0348723411.USD","HUM","LU0985481810.HKD","LU0251142724.SGD","LU1983260115.SGD","AVNT","EMR","OP.USD.HKCC","ASTE","LU1551013425.SGD","LU2756315318.SGD"],"gpt_icon":1},{"id":"2580409522","title":"Arvinas to Present Preclinical Data for ARV-393 at 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580409522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580409522?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:00","pubTimestamp":1762203618,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has announced that preclinical data for its PROTAC BCL6 degrader, ARV-393, in combination with glofitamab, a CD20xCD3 bispecific antibody, will be presented at the 2025 American Society of Hematology  Annual Meeting. The poster presentation is scheduled for December 6, 2025, from 5:30 PM to 7:30 PM ET in Orlando, Florida. The company stated that the full abstract is available through the ASH online program. The results have not yet been presented and are scheduled for future presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7LK4Dg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","NDAQ","BK4588","ARVN"],"gpt_icon":0},{"id":"2580215781","title":"Arvinas Inc  expected to post a loss of 79 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215781","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215781?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:32","pubTimestamp":1762176764,"startTime":"0","endTime":"0","summary":"Arvinas Inc  expected to post a loss of79cents a share - Earnings Preview Arvinas Inc ARVN.OQ ARVN.O is expected to  show a fall in quarterly revenue when it reports  results on November 5 for the per","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2580975582","title":"Arvinas Inc. to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580975582","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580975582?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171222,"startTime":"0","endTime":"0","summary":"Arvinas Inc., a clinical-stage biotechnology company focused on targeted protein degradation, will participate in Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11. The company's management will give a presentation, which will be available via live audio webcast on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL63np7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4588","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","ARVN","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4007","BK4585","IE00BKPKM429.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2579914302","title":"Arvinas Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2579914302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579914302?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:46","pubTimestamp":1761824760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 07:46 ET (11:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2578540525","title":"Arvinas presents preclinical data for ARV-806","url":"https://stock-news.laohu8.com/highlight/detail?id=2578540525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578540525?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:05","pubTimestamp":1761336315,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecula...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-presents-preclinical-data-for-arv-806-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-presents-preclinical-data-for-arv-806-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2578547450","title":"Arvinas Unveils Promising Phase 1 Trial Data for KRAS G12D Degrader ARV-806 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578547450","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578547450?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:00","pubTimestamp":1761336016,"startTime":"0","endTime":"0","summary":"Arvinas Inc. has announced preclinical data for its investigational drug ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrated that ARV-806 showed robust and durable KRAS G12D degradation, resulting in significant tumor growth inhibition in preclinical models of pancreatic, colorectal, and lung cancer. ARV-806 is designed to target both the ON and OFF forms of KRAS G12D and is currently being evaluated in a Phase 1 clinical trial for patients with KRAS G12D-mutated advanced solid tumors . The company also presented findings on orally bioavailable pan-KRAS degraders capable of targeting multiple KRAS variants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLbsWLyW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","ARVN","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4007","BK4112","IE00BKPKM429.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":0.0245},{"period":"1month","weight":0.16},{"period":"3month","weight":0.662},{"period":"6month","weight":0.7564},{"period":"1year","weight":-0.4721},{"period":"ytd","weight":-0.3229}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.025374},{"month":2,"riseRate":0.571429,"avgChangeRate":0.011057},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.187738},{"month":4,"riseRate":0.571429,"avgChangeRate":0.096543},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.132272},{"month":6,"riseRate":0.857143,"avgChangeRate":0.012839},{"month":7,"riseRate":0.714286,"avgChangeRate":0.109648},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06004},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.073956},{"month":10,"riseRate":0.5,"avgChangeRate":0.007881},{"month":11,"riseRate":0.75,"avgChangeRate":0.171233},{"month":12,"riseRate":0.625,"avgChangeRate":0.360212}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction